Back to Report Store Home

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • Published: Feb-2016
  • Report Code: GBIHC402MR
  • Report Format: pdf

Description

List of Tables

Table 1: Tumor, regional lymph Node and Metastasis Staging, 2010–2013 14

Table 2: US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 15

Table 3: Breast Cancer Histopathological and Molecular Classification 15

Table 4: Key Features and Pipeline Activity of FGFR3 41

Table 5: Key Features and Pipeline Activity of FGFR4 42

Table 6: Pipeline Programs Targeting FGFR4 42

Table 6: Key Features and Pipeline Activity of HER3 43

Table 7: Key Features and Pipeline Activity of PDPK1 44

Table 8: Key Features and Pipeline Activity of Akt1 46

Table 9: Key Features and Pipeline Activity of Akt2 46

Table 10: Key Features and Pipeline Activity of Akt3 47

Table 11: Key Features and Pipeline Activity of PI3K-alpha 49

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards